US Bancorp DE Raises Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

US Bancorp DE raised its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 4,933.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,329 shares of the biotechnology company’s stock after buying an additional 4,243 shares during the quarter. US Bancorp DE’s holdings in Enanta Pharmaceuticals were worth $45,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC bought a new position in shares of Enanta Pharmaceuticals in the second quarter valued at approximately $35,000. State Board of Administration of Florida Retirement System purchased a new stake in Enanta Pharmaceuticals in the 1st quarter worth approximately $118,000. Virtu Financial LLC bought a new position in Enanta Pharmaceuticals in the 1st quarter valued at $191,000. Quest Partners LLC grew its position in shares of Enanta Pharmaceuticals by 511.2% during the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 9,692 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Enanta Pharmaceuticals by 35.4% in the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after purchasing an additional 7,287 shares during the period. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Trading Down 5.9 %

Shares of Enanta Pharmaceuticals stock opened at $9.53 on Monday. The firm has a market capitalization of $201.93 million, a PE ratio of -1.75 and a beta of 0.56. Enanta Pharmaceuticals, Inc. has a 12 month low of $8.46 and a 12 month high of $17.80. The business’s 50-day moving average price is $11.36 and its 200-day moving average price is $12.55.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. JPMorgan Chase & Co. cut their price objective on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th. JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 target price on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 9th. Finally, Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Enanta Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.